Patient P-03140
Therapy response
Improving
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Favorable
Nutritional resilience
Improving
Discontinuation risk
2%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S20
- Day 24 AD-05 recommended — Adherence Support AD-05
- Day 25 Patient accepted — Started AD-05 in the companion
- Day 30 GI symptom burden −18% vs expected — Adherence Support AD-05
- Day 36 Tolerance state changed — Unstable → Improving
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Nutritional resilience+7
- GI instability-5
- Toxicity+5
- Treatment adherence+4
- Inflammatory activity-2
What helped?
- Adherence Support AD-05Day 24Result: symptom burden −18%
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log6.4/10
stable · -0.1 vs previous 14 d
Stress level
Daily log3/10
worsening · +0.2 vs previous 14 d
Pessimism score
Daily log1.9/10
worsening · +0.3 vs previous 14 d
Sleep quality
Wearable53.7/100
worsening · -2.8 vs previous 14 d
Libido
Daily log6.1/10
stable · +0.1 vs previous 14 d
HRV
Wearable64.4 ms
stable · -0.1 vs previous 14 d
Toxicity
Blood6.1/100
improving · -3.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 98 from the failing basin, 14 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -4.1 next day on high-intake days · n 22
Would not help
- Keep alcohol lowGI +3.5 next day on high-intake days · n 24
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.1supporter · 95%
- Alcohol+3.5detractor · 95%
- Histamine load-1.2no signal · 30%
- Lactose+1.2no signal · 31%
- Dietary fat load-1.1no signal · 25%
- Caffeine+0.7no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
- Autonomic recovery ↑20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.9 · butyrate capacity 68/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 66 ms
- Sleep
- 6.0 h
- Steps
- 6,635
- Resting HR
- 64 bpm
Daily log: GI score 8, nutritional resilience 75, adherence 97.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03161 | 60% | S20 | — | — | 82 |
| P-03089 | 56% | S13 | — | — | 82 |
| P-03310 | 54% | S02 | — | — | 78 |
| P-03063 | 53% | S05 | — | — | 82 |
| P-03397 | 53% | S19 | GI-04 | no change | 84 |
| P-03018 | 52% | S05 | ME-01 | improved | 84 |
| P-03165 | 52% | S06 | NP-02 | improved | 79 |
| P-03331 | 51% | S01 | — | — | 86 |
| P-03448 | 51% | S14 | — | — | 77 |
| P-03079 | 50% | S18 | — | — | 84 |
| P-03387 | 50% | S19 | — | — | 83 |
| P-03001 | 49% | S04 | CR-01 | improved | 87 |